Literature DB >> 19903496

Study of Andes virus entry and neutralization using a pseudovirion system.

Neelanjana Ray1, Jillian Whidby, Shaun Stewart, Jay W Hooper, Andrea Bertolotti-Ciarlet.   

Abstract

Andes virus (ANDV), a member of the Hantavirus genus in the family Bunyaviridae, causes an acute disease characteristic of New-World hantaviruses called hantavirus pulmonary syndrome (HPS). HPS is a highly pathogenic disease with a case-fatality rate of 40%. ANDV is the only hantavirus reported to spread directly from human-to-human. The aim of the present study was to develop a quantitative and high-throughput pseudovirion assay to study ANDV infection and neutralization in biosafety level 2 facilities (BSL-2). This pseudovirion assay is based on incorporation of ANDV glycoproteins onto replication-defective vesicular stomatitis virus (VSV) cores in which the gene for the surface G protein has been replaced by that encoding Renilla luciferase. Infection by the pseudovirions can be quantified by luciferase activity of infected cell lysates. ANDV pseudovirions were neutralized by ANDV-specific antisera, and there was good concordance between specificity and neutralization titers of ANDV hamster sera as determined by our pseudovirion assay and a commonly used plaque reduction neutralization titer (PRNT) assay. In addition, the pseudovirions were used to evaluate the requirements for ANDV entry, like pH dependency and the role of beta3 integrin, the reported receptor for other pathogenic hantaviruses, on entry. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903496     DOI: 10.1016/j.jviromet.2009.11.004

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  21 in total

1.  Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

Authors:  May S ElSherif; Catherine Brown; Donna MacKinnon-Cameron; Li Li; Trina Racine; Judie Alimonti; Thomas L Rudge; Carol Sabourin; Peter Silvera; Jay W Hooper; Steven A Kwilas; Nicole Kilgore; Christopher Badorrek; W Jay Ramsey; D Gray Heppner; Tracy Kemp; Thomas P Monath; Teresa Nowak; Shelly A McNeil; Joanne M Langley; Scott A Halperin
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

2.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Authors:  Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

3.  Characterization of Vesicular Stomatitis Virus Pseudotypes Bearing Essential Entry Glycoproteins gB, gD, gH, and gL of Herpes Simplex Virus 1.

Authors:  Henry B Rogalin; Ekaterina E Heldwein
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

4.  Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.

Authors:  Kyle S Brown; David Safronetz; Andrea Marzi; Hideki Ebihara; Heinz Feldmann
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

5.  Hantavirus entry: Perspectives and recent advances.

Authors:  Eva Mittler; Maria Eugenia Dieterle; Lara M Kleinfelter; Megan M Slough; Kartik Chandran; Rohit K Jangra
Journal:  Adv Virus Res       Date:  2019-08-07       Impact factor: 9.937

6.  Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Authors:  Joseph W Golden; Piet Maes; Steven A Kwilas; John Ballantyne; Jay W Hooper
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

7.  IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.

Authors:  Rajini Mudhasani; Julie P Tran; Cary Retterer; Sheli R Radoshitzky; Krishna P Kota; Louis A Altamura; Jeffrey M Smith; Beverly Z Packard; Jens H Kuhn; Julie Costantino; Aura R Garrison; Connie S Schmaljohn; I-Chueh Huang; Michael Farzan; Sina Bavari
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

8.  A Haploid Genetic Screen Identifies Heparan Sulfate Proteoglycans Supporting Rift Valley Fever Virus Infection.

Authors:  Amber M Riblett; Vincent A Blomen; Lucas T Jae; Louis A Altamura; Robert W Doms; Thijn R Brummelkamp; Jason A Wojcechowskyj
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

9.  Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection.

Authors:  Taylor B Engdahl; Natalia A Kuzmina; Adam J Ronk; Chad E Mire; Matthew A Hyde; Nurgun Kose; Matthew D Josleyn; Rachel E Sutton; Apoorva Mehta; Rachael M Wolters; Nicole M Lloyd; Francisca R Valdivieso; Thomas G Ksiazek; Jay W Hooper; Alexander Bukreyev; James E Crowe
Journal:  Cell Rep       Date:  2021-05-04       Impact factor: 9.423

10.  Chinese hamster ovary cell lines selected for resistance to ebolavirus glycoprotein mediated infection are defective for NPC1 expression.

Authors:  Kathleen M Haines; Nathan H Vande Burgt; Joseph R Francica; Rachel L Kaletsky; Paul Bates
Journal:  Virology       Date:  2012-06-21       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.